WO2020048341A1 - 哺乳动物细胞重组抗人tk1的鸡源的单克隆抗体、单链抗体及其制备方法和应用 - Google Patents

哺乳动物细胞重组抗人tk1的鸡源的单克隆抗体、单链抗体及其制备方法和应用 Download PDF

Info

Publication number
WO2020048341A1
WO2020048341A1 PCT/CN2019/102619 CN2019102619W WO2020048341A1 WO 2020048341 A1 WO2020048341 A1 WO 2020048341A1 CN 2019102619 W CN2019102619 W CN 2019102619W WO 2020048341 A1 WO2020048341 A1 WO 2020048341A1
Authority
WO
WIPO (PCT)
Prior art keywords
seq
monoclonal antibody
amino acid
chain
sequence shown
Prior art date
Application number
PCT/CN2019/102619
Other languages
English (en)
French (fr)
Inventor
李作生
陈湖
李惠军
党利
梁丽雯
方聪
谭俊烨
何艾伦
斯库格斯文
周际
Original Assignee
华瑞同康生物技术（深圳）有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 华瑞同康生物技术（深圳）有限公司 filed Critical 华瑞同康生物技术（深圳）有限公司
Publication of WO2020048341A1 publication Critical patent/WO2020048341A1/zh
Priority to US17/191,710 priority Critical patent/US20210277147A1/en

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6871—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an enzyme
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/23—Immunoglobulins specific features characterized by taxonomic origin from birds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/42—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a HA(hemagglutinin)-tag
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
    • G01N2333/91215—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases with a definite EC number (2.7.1.-)
    • G01N2333/9122—Thymidine kinase (2.7.1.21)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7023—(Hyper)proliferation

Definitions

  • the present invention relates to the field of bioengineering, in particular to monoclonal antibodies, single chain antibodies, and preparation methods and applications thereof, and more particularly, to monoclonal antibodies, single chain antibodies, isolated nucleic acids, vectors, recombinant cells, and preparation of monoclonal antibodies.
  • Thymidine kinase 1 is a special kinase that catalyzes thymidine (TdR) to 1-phosphate thymidine (TMP).
  • TdR thymidine
  • TMP 1-phosphate thymidine
  • TK1 is a cell cycle-dependent enzyme and is mainly found in the cytoplasm.
  • S phase The replication of chromosomal DNA in mammalian cells is restricted to a specific period in the cell cycle, which is called the S phase.
  • the enzymatic activities of many enzymes required for DNA precursor synthesis and DNA replication increase when cells enter the S phase, and decrease after DNA synthesis is completed.
  • TK thymidylate synthetase
  • ribonucleoside diphosphate reductase ribonucleoside diphosphate reductase
  • dihydrofolate reductase a type of special S-phase enzymes
  • TK thymidylate synthetase
  • ribonucleoside diphosphate reductase ribonucleoside diphosphate reductase
  • dihydrofolate reductase dihydrofolate reductase
  • TK concentration detection generally uses TK1 protein as the antigen to prepare single / polyclonal anti-human TK1 antibodies, but the sensitivity and specificity of antibodies are generally not high.
  • an object of the present invention is to propose a single-chain antibody or a monoclonal antibody, which is an IgY single-chain antibody or a monoclonal antibody against TK1, which has high affinity and avoids non-specific reactions of mammalian IgG. Because the molecular weight is smaller, it is easier to enter the cell.
  • the main antibodies used are mouse-derived monoclonal antibodies against human thymidine kinase 1 (STK1). 1 molecule has only 84% genetic homology with mouse thymidine kinase 1 molecule and 87% amino acid homology.
  • Immunoglobulins are highly conserved among mammalian breeds and react with a variety of proteins from mammals and bacteria, limiting their use in immunodiagnostics. Due to the phylogenetic differences of chickens, chicken IgY is widely used in immunity. IgY is the major low molecular weight immunoglobulin of oviparous animals.
  • IgY can be easily obtained from immunized chicken eggs, and IgY has great advantages in diagnostic and therapeutic applications.
  • IgY is a polyclonal antibody. Due to the lack of heterophilic antibodies, rheumatoid factors and human anti-mouse antibodies and complement components, the background of the reaction detection is low. In immunoassays, heterophilic antibodies, rheumatoid factors and human anti-mouse antibodies are considered to be the biggest inducers of false positives and false negatives. Heterophilic antibodies have low affinity, and IgY does not bind to a variety of immune Fc receptor molecules found in mammals. Therefore, in the immunohistochemical operation of mammalian tissues, the use of IgY antibodies can effectively reduce the false Positive signal.
  • IgY is a polyclonal antibody. Compared with monoclonal antibodies, the inherent defects of polyclonal antibodies limit the potential of IgY applications.
  • the inventors used recombinant antibodies to prepare single-chain IgY antibodies, and used DNA recombination technology to fuse and express the antibody heavy chain variable region and light chain variable region genes through a short peptide. It has the antigen specificity and affinity of natural antibodies. It has no Fc segment, so it cannot bind to Fc receptors of cells, so it is more useful as a drug-oriented carrier. At the same time, because of its small molecular weight (about 30kDa, the antibody is about 150kDa), easy to pass through the vascular wall and solid tumors, which is conducive to the treatment of drugs.
  • E. coli expression system The most commonly used expression systems for antibody recombination are the E. coli expression system and mammalian cell expression system, but each has its advantages and disadvantages.
  • High expression is obtained in E. coli, which is easy to prepare in large quantities, but often contains non-biologically active inclusion bodies, and the amount of soluble expression is very small. In particular, it is difficult to modify effectively during translation and expression, resulting in loss of biological activity, which limits its biological activity. application.
  • the inventor used a mammalian expression system to express a monoclonal antibody against TK1 IgY, not only expressing an antibody molecule that specifically binds to TK1, but also avoiding the defects of non-antigen-specific reactions inherent in mammalian antibody Fc fragments The specificity and sensitivity of the monoclonal antibody are high.
  • the use of the recombinant single-chain antibody against human TK1 molecule to detect TK1 molecule in human serum can overcome the shortcomings of low affinity of mouse monoclonal antibodies and high background caused by cross-reactivity, and can improve the easy access of small molecule antibodies Intracellular can improve the detection effect in immunohistochemistry.
  • the invention provides a monoclonal antibody.
  • the light chain of the monoclonal antibody has the amino acid sequence shown in SEQ ID NO: 1, specifically, the amino acid sequence shown in SEQ ID NO: 1 may be a light chain variable region sequence, heavy
  • the chain has the amino acid sequence shown in SEQ ID NO: 2, specifically, the amino acid sequence shown in SEQ ID NO: 2 may be a heavy chain variable region sequence.
  • the monoclonal antibody according to the embodiment of the present invention is a recombinant IgY monoclonal antibody against TK1, which has high affinity, low cross-reactivity, and effectively avoids non-specific reactions of IgG. Compared with the smaller molecular weight, it is easier to enter the cell, which can improve the detection effect in immunohistochemistry, and it is easy to pass through the blood vessel wall and solid tumor, which can be beneficial to the treatment of drugs.
  • monoclonal antibodies according to the above embodiments of the present invention may also have the following additional technical features:
  • the monoclonal antibody further includes: a linker peptide having the amino acid sequence shown in SEQ ID NO: 3.
  • the linker peptide connects the C-terminus of the light chain variable region and the N-terminus of the heavy chain variable region to form a monoclonal antibody.
  • the linker peptide has good flexibility and does not affect the correct folding of the variable regions of the heavy and light chains.
  • the monoclonal antibody further includes at least one of the following expression elements: a signal peptide having the amino acid sequence shown in SEQ ID NO: 4; a tag having the SEQ ID NO : 5 amino acid sequence shown.
  • the signal peptide guides the secretion of the recombinant monoclonal antibody out of the cell, which is beneficial to the purification of the recombinant monoclonal antibody.
  • a signal peptide is linked to the N-terminus of the light chain variable region of the monoclonal antibody.
  • the signal peptide of the embodiment of the present invention is a murine IL-2 signal peptide commonly used for antibody recombination of the CHO expression system; and a linker peptide is used to connect a tag sequence to the antibody and isolate the antibody by the tag sequence, wherein the tag is a human influenza virus Hemagglutinin 9 peptide.
  • the tag may be linked to the C-terminus of the heavy chain variable region of the monoclonal antibody.
  • the monoclonal antibody has an amino acid sequence shown in SEQ ID NO: 6.
  • the invention provides a single chain antibody.
  • the light chain of the single-chain antibody has the amino acid sequence shown in SEQ ID NO: 1
  • the heavy chain has the amino acid sequence shown in SEQ ID NO: 2.
  • single-chain antibody is an antibody in which the variable region of an antibody heavy chain and the variable region of a light chain are linked by a short peptide. Specifically, the single-chain antibody has no constant region, but the functions and immune effects of the single-chain antibody and the monoclonal antibody in the embodiment of the present invention are the same and similar.
  • the single-chain antibody further includes a linker peptide having the amino acid sequence shown in SEQ ID NO: 3.
  • the linker peptide connects the N-terminus of the light chain variable region and the C-terminus of the heavy chain variable region to form a single chain antibody.
  • the linker peptide has good flexibility and does not affect the correct folding of the variable regions of the heavy and light chains.
  • the single-chain antibody further includes at least one of the following expression elements: a signal peptide having the amino acid sequence shown in SEQ ID NO: 4; a tag having the SEQ ID NO : 5 amino acid sequence shown.
  • the signal peptide guides the secretion of the recombinant single-chain antibody out of the cell, which is beneficial to the purification of the recombinant single-chain antibody.
  • the signal peptide of the embodiment of the present invention is a murine IL-2 signal peptide commonly used for antibody recombination of the CHO expression system; and a linker peptide is used to connect a tag sequence to the antibody and isolate the antibody by the tag sequence, wherein the tag is a human influenza virus Hemagglutinin 9 peptide.
  • the invention provides a nucleic acid.
  • the nucleic acid encodes the aforementioned monoclonal antibody or single chain antibody.
  • the inventors have surprisingly found that the nucleic acid-encoded anti-TK1 IgY single-chain antibody or monoclonal antibody has high affinity and low cross-reactivity, and effectively avoids non-specific reactions of mammalian IgG.
  • the relative molecular weight of the monoclonal antibody is smaller, and it is easier to enter the cell, which can improve the detection effect in immunohistochemistry, and it is easy to pass through the blood vessel wall and solid tumor, which can be beneficial to the treatment of the drug.
  • the nucleic acid further includes at least one of the following expression elements:
  • KOZAK sequence which has the nucleotide sequence shown in SEQ ID NO: 7, which can be combined with a translation initiation factor to mediate the translation initiation of an mRNA containing a 5 'cap structure.
  • the signal peptide has the nucleotide sequence shown in SEQ ID NO: 8, and the signal peptide guides the secretion of the recombinant single chain antibody to the outside of the cell.
  • the tag has the nucleotide sequence shown in SEQ ID NO: 9, and the antibody is separated by the tag sequence, wherein the tag is the sequence of human influenza virus hemagglutinin
  • the nucleic acid has a nucleotide sequence shown in SEQ ID NO: 10.
  • the 3'-end AGATCT sequence and the 5-end CCGCGG are restriction sites.
  • DNA is transcribed into mRNA, and mRNA is translated into protein after being processed by splicing.
  • the so-called coding sequence is a DNA sequence corresponding to the protein sequence, and the sequence does not contain other sequences that are not corresponding to the protein. Regardless of sequence changes during mRNA processing, in short, the coding sequence corresponds exactly to the codons of the protein, in other words, the coding sequence is the sequence that encodes a protein product.
  • the nucleic acid further includes a nucleotide sequence in which one or more bases are substituted, deleted, or modified by the nucleotide sequence shown in SEQ ID NO: 10, which means that the nucleotide sequence is separately or simultaneously The 5 'end and / or 3' end of the nucleotide sequence, and / or the sequence is performed internally, for example, not more than 2-60, or not more than 2-40, or not more than 3-30, or not more than 4- Substitutions, deletions, and modifications of 15 bases, or no more than 5-10, or no more than 6-8, each expressed as a consecutive integer.
  • the nucleic acid further includes a nucleotide sequence in which the nucleotide sequence shown in SEQ ID NO: 10 is substituted, deleted, or modified by adding one or more bases as described above.
  • the nucleotide sequences shown have the same or similar functions as anti-TK1 single chain antibodies or monoclonal antibodies.
  • the present invention provides a recombinant vector.
  • the recombinant vector comprises the aforementioned nucleic acid.
  • the vector according to the embodiment of the present invention can secrete and produce an anti-TK1 single-chain antibody or monoclonal antibody.
  • the single-chain antibody or monoclonal antibody has good immunoreactivity, high affinity, low cross-reactivity, and effectively avoids The non-specific response of IgG.
  • the single-chain antibody or monoclonal antibody has a smaller molecular weight and is easier to enter into the cell. It can improve the detection effect in immunohistochemistry, and it is easy to pass through the blood vessel walls and entities. Tumors can be beneficial for the treatment of drugs.
  • the vector can be obtained, for example, by inserting the aforementioned nucleotide sequence into a cloning vector or an expression vector, or can be obtained by artificial synthesis.
  • the vector of the recombinant vector is a eukaryotic vector, such as a pIRES2-EGFP vector.
  • a eukaryotic vector such as a pIRES2-EGFP vector.
  • the present invention provides a recombinant cell.
  • the recombinant cell contains the aforementioned vector.
  • the recombinant cells according to the embodiments of the present invention can secrete and produce anti-TK1 single-chain antibodies or monoclonal antibodies.
  • the single-chain antibodies or monoclonal antibodies have good immunoreactivity, high affinity, and low cross-reactivity, which effectively avoids non-specific reactions of IgG.
  • the single-chain antibody or monoclonal antibody Compared with IgG, the single-chain antibody or monoclonal antibody has a smaller relative molecular weight and is easier to enter into the cell, which can improve the detection effect in immunohistochemistry, and is easy to pass through the blood vessel wall and solid tumor, which can be beneficial Drugs for treatment.
  • the recombinant cell can be obtained by transforming the aforementioned vector into a host cell.
  • the eukaryotic expression vector of the embodiment of the present invention can be used to transfect CHO cells (Chinese hamster ovary cells, belonging to a type of ovarian fibroblast tumor cell) for 16 hours to observe obvious expression (green fluorescent protein labeling).
  • the present invention provides a method for preparing the aforementioned monoclonal antibody or the aforementioned single-chain antibody.
  • the method comprises: culturing the aforementioned recombinant cell under conditions suitable for protein expression and secretion, so as to obtain the monoclonal antibody or single-chain antibody. Therefore, the monoclonal antibody or single-chain antibody prepared by this method has good immunoreactivity, high affinity, low cross-reaction, and effectively avoids non-specific reactions of IgG.
  • the single-chain antibody or monoclonal antibody Relative to the molecular weight is smaller, easier to enter the cell, can improve the detection effect in immunohistochemistry, and easy to pass through the blood vessel wall and solid tumors, which can be beneficial to the treatment of drugs.
  • the method further comprises purifying the single-chain antibody or the monoclonal antibody, and the purifying treatment may be performed by agarose gel column affinity chromatography of the TK1-31 amino acid coupled polypeptide antigen.
  • the single-chain antibody or monoclonal antibody obtained by this purification treatment has high purity and activity.
  • the invention provides an immunoconjugate.
  • the immunoconjugate includes: the aforementioned monoclonal antibody, or the aforementioned single-chain antibody; and a coupling moiety selected from the group consisting of a drug, a toxin, a cytokine, a radionuclide, or an enzyme.
  • a coupling moiety selected from the group consisting of a drug, a toxin, a cytokine, a radionuclide, or an enzyme.
  • the present invention provides a detection strip or a detection kit.
  • the detection strip and the detection kit contain the aforementioned monoclonal antibody, the aforementioned single-chain antibody, the aforementioned immunoconjugate, or a combination thereof with a detectable label. Therefore, the detection strip or the detection kit can be used to detect TK1, and then judge the abnormal proliferation of cells.
  • the detection strip or the detection kit has high detection sensitivity and specificity.
  • the detectable label is selected from the group consisting of a colloidal gold label, a fluorescent label, an isotope label, and an enzyme label.
  • the enzyme label is an HRP enzyme label.
  • the present invention provides the use of the aforementioned monoclonal antibody, the aforementioned single-chain antibody, the aforementioned immunoconjugate, and the aforementioned detection strip or detection kit for detecting abnormal cell proliferation. Therefore, the aforementioned monoclonal antibody or single-chain antibody, the aforementioned immunoconjugate, and the aforementioned detection strip or detection kit are used to detect TK1, thereby determining the abnormal proliferation of cells, and the detection sensitivity and specificity are high.
  • the abnormal cell proliferation may include pregnancy, tissue proliferation, and tumor, and the sensitivity and accuracy of detection are high.
  • FIG. 1 shows a schematic diagram of a PCR identification result of a single-chain antibody according to an embodiment of the present invention
  • FIG. 2 shows a schematic diagram of a result of double-digested agarose electrophoresis according to an embodiment of the present invention
  • FIG. 3 is a schematic diagram of a fluorescence microscopic observation picture of a CHO cell transfected with a single-chain antibody gene eukaryotic expression vector according to an embodiment of the present invention.
  • the expression method of the anti-TK1 single chain antibody provided by the embodiment of the present invention is as follows:
  • the phage display system was used to screen a single-chain antibody gene with the activity of the C-terminal 31 peptide of human-derived molecule TK1 as a template.
  • sequence suitable for the construction of an eukaryotic expression vector was amplified according to the following procedure.
  • the thymidine kinase 1 (TK1) molecular gene is 702 bp in length, encoding 234 amino acids, and the C-terminal 31 peptide is located at positions 195 to 225aa of the full-length protein molecule.
  • Amplification system PCR reaction system: 10 * PCR buffer
  • the amplified sequence contains the restriction sites required for construction, the kozak sequence GCCACCATGG required for eukaryotic expression, the N-terminal signal peptide MGRMQLLSCIALSLALVTNS sequence required for animal cell secretion expression, and the linker sequence GGGSGGGGSGGGGSGGGS for the heavy and light chain variable regions for detection. And purified tag sequences (human influenza virus hemagglutinin 9 peptide, YPYDVPDYA sequence).
  • the PCR amplified product was identified by agarose electrophoresis, and the target fragment was recovered.
  • the fragments recovered by electrophoresis purification and the expression vector pIRSE2-EGFP were double-digested with BglII and SacII, respectively. After digestion, single-chain antibody fragments and vector linearized fragments were recovered by electrophoresis to remove small fragments and enzyme protein molecules at both ends of the excision. The two recovered fragments are mixed in an equimolar ratio and ligated with T4 ligase to obtain an expression vector for ligating the gene of interest.
  • the product was recovered by digestion with BglII, 10 * cutsmart buffer, 5ul, SacIIenzyme 1ul, sterilized deionized water to 50ul, 37 ° C for 1h, and the product was purified and recovered by Qiagen gel recovery kit.
  • the ligation product was directly transformed by thermal shock or electrotransformed into DH5 ⁇ competent cells (Solarbio, C1100). After transformation, all transformed bacteria were plated on agar plates containing kanamycin and cultured at 37 ° C for 16-20 hours (h). From the bacterial colonies growing on the plate, pick up 5-10 colonies after overnight at 37 ° C, place them in 5 ml (mL) LB medium containing kanamycin and incubate for 16 hours to extract the plasmid. After the plasmid was purified and double-digested with BglII and SacII, a clone of 800bp fragment can be cut (as shown in Figure 1), the sequence was determined, and the target gene was determined again.
  • the determined sequence was analyzed by DNAMANV6, and the determined sequence was exactly the same as the optimized sequence designed.
  • the transformants were positively amplified by single-chain antibody gene PCR amplification.
  • the transformant colonies were amplified and cultured.
  • the plasmid DNA was extracted and then identified by double digestion with BglII and SacII. The results are shown in Figure 2. Fragmented DNA fragments of the same size.
  • the plasmid DNA of the correct size was sent to Kingsley Biotechnology for sequence determination.
  • the determined sequence was exactly the same as the optimized sequence designed.
  • Chinese hamster ovary cells (Chinese Hamster Ovary, CHO), isolated from an adult female hamster ovary in 1957, Colorado, USA, Dr. Theodore T. Puck, is an epithelial adherent cell and is a widely used cell line in biological engineering.
  • the cells are immortal and can be passaged for more than one hundred generations.
  • CHO cells have another advantage in the use of genetic engineering. This cell is a fibroblast, which is a non-secretory cell. It rarely secretes CHO endogenous proteins, so it is very beneficial for the isolation and purification of target proteins. .
  • CHO cells can form active dimers with glycosylation. They are ideal hosts for the expression of complex biological macromolecules. The obtained antibody proteins have biological characteristics completely similar to those naturally produced by humans.
  • a host cell using CHO cells as an expression vector are ideal hosts for the expression of complex biological macromolecules. The obtained antibody proteins have biological characteristics completely similar to those naturally produced by humans.
  • a 24-well cell culture plate was selected. In each well, CHO cells were passaged 24 hours before transfection, and the cells on the day of transfection reached an abundance of 70% to 90%. Among them, when the abundance was 70% to 90%, the cells were suspended. Transfection should be in the logarithmic growth phase.
  • the single-chain antibody of recombinant IgY contains not only a hypervariable region binding to TK1, but also a highly conserved backbone region (FR).
  • the 9-peptide tag of HA of human influenza hemagglutinin was also added. Therefore, in the detection of recombinant single chain antibodies by indirect ELISA, the biotin-labeled anti-full-length IgY secondary antibody and horseradish peroxidase-labeled anti-human influenza hemagglutinin HA 9-peptide monoclonal antibodies were Label the antibody and detect the recombinant anti-TK1 single chain antibody expressed in CHO cells. The supernatant of the transfected cells was collected, and the expression level of the recombinant single chain antibody was detected by ELISA.
  • the specific method is as follows:

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Plant Pathology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)

Abstract

哺乳动物细胞重组抗人TK1的鸡源的单克隆抗体、单链抗体及其制备方法和应用，单克隆抗体的轻链具有SEQ ID NO:1所示的氨基酸序列，重链具有SEQ ID NO:2所示的氨基酸序列。

Description

哺乳动物细胞重组抗人TK1的鸡源的单克隆抗体、单链抗体及其制备方法和应用
本申请要求于2018年09月04日提交的申请号为201811026810.9的中国专利申请的权益，并将其全部引入本文。
技术领域
本发明涉及生物工程领域，具体地，涉及单克隆抗体、单链抗体及其制备方法和应用，更具体地，涉及单克隆抗体、单链抗体、分离的核酸、载体、重组细胞、制备单克隆抗体的方法、免疫偶联物、检测条或检测试剂盒，以及单克隆抗体、免疫偶联物和检测条或检测试剂盒在检测细胞异常增殖的用途。
背景技术
胸苷激酶1(TK1)是一特殊激酶，催化胸苷(TdR)为1-磷酸胸苷酸(TMP)。TK1是细胞周期依赖酶，主要存在于细胞质中。哺乳动物细胞中染色体DNA的复制是限制在细胞周期中的某一特定期内进行的，它称为S期。DNA前体合成和DNA复制过程中所需要的许多酶的酶活性在细胞进入S期时升高，并在DNA合成完成后降低。一类型类的S期特殊酶，包括TK、胸苷酸合成酶、二磷酸核糖核苷还原酶、二氢叶酸还原酶，其特征是这类型酶被大幅度诱导升高。这类酶活性的改变，揭示了存在着两种截然不同的调节机制:一种启动方式是酶活性在S期升高；另一种则是使酶活降低，并恢复到S期之前的水平。血清的胸苷激酶1的检测具有重要临床检测意义。
目前，检测胸苷激酶1(STK1)的产品不多，主要是检测人血清中胸苷激酶1(STK1)的产品和检测免疫组化用的标记抗体。TK浓度检测一般采用TK1蛋白质作抗原，制备单/多克隆抗人TK1抗体，但抗体的灵敏度和特异性普遍不高。
由此，现有的TK1抗体有待改进。
发明内容
本发明旨在至少解决现有技术中存在的技术问题之一。为此，本发明的一个目的在于提出一种单链抗体或单克隆抗体，该抗体为抗TK1的IgY的单链抗体或单克隆抗体，亲和力高，避免了哺乳动物IgG的非特异性反应，相对于分子量更小，更容易进入到细胞内。
需要说明的是，本发明是基于发明人的下列工作而完成的：
目前，单/多克隆抗人TK1抗体的灵敏度和特异性大多不高，主要是应用的抗体是鼠源的抗人源胸苷激酶1(STK1)的单克隆抗体，但由于人源胸苷激酶1分子与鼠的胸苷激酶1分子基因同源性仅为84％，氨基酸同源性仅为87％，应用人源胸苷激酶1(STK1)蛋白分子为抗原诱导的小鼠的免疫应答水平低，因此筛选的单克隆抗体的亲和性也低；再加上鼠源的单克隆抗体作为检测试剂，因其异嗜性抗体，类风湿因子和人抗鼠抗体而导致假阳性和假阴性和检测的敏感性低。免疫球蛋白在各哺乳动物品种中具有很高的保守性，以及与哺乳动物和细菌的多种蛋白反应的性质，限制了在免疫诊断上的应用。由于鸡的系统发育 差异，鸡IgY在免疫上的应用广泛。IgY是卵生动物主要低分子量免疫球蛋白。IgY可以从免疫的鸡鸡蛋中轻易获得，IgY在诊断和治疗应用中具有很大的优势。但IgY是多克隆抗体，由于缺乏异嗜性抗体、类风湿因子和人抗鼠抗体和补体成分而使得反应检测背景低。在免疫实验中，异嗜性抗体、类风湿因子和人抗鼠抗体被认为是产生假阳性和假阴性最大诱因。异嗜性抗体亲和力低，IgY并不与发现的哺乳动物的多种免疫细Fc受体分子结合，因此，哺乳动物组织的免疫组化操作中，应用IgY抗体比用IgG抗体可以有效地降低假阳性信号。但是，IgY是多克隆抗体，相对于单克隆抗体，多克隆抗体的固有缺陷限制了IgY的应用潜力。
发明人利用重组抗体制备IgY的单链抗体，利用DNA重组技术将抗体重链可变区和轻链可变区基因通过一个短肽连接后融合表达出来的抗体片段。它具备天然抗体的抗原特异性和亲和性，它没有Fc段，故不能与细胞的Fc受体结合，因此更有利于作为药物导向载体；同时由于它的分子量较小(约30kDa，抗体约为150kDa)，易于通过血管壁和实体瘤，有利于作用药物进行治疗。
抗体的重组目前最常用的表达系统是大肠杆菌表达系统和哺乳动物细胞表达系统，但各有其优缺点。在大肠杆菌中获得高表达，易于大量制备，但往往形成不具生物活性的包涵体，而可溶性表达量很少，尤其翻译表达时难以进行有效的修饰而导致生物活性的丧失，从而限制了它的应用。发明人采用哺乳动物表达系统表达抗TK1的IgY的单克隆抗体，不仅表达出能与TK1特异性结合的抗体分子，而且还避免了哺乳动物抗体Fc片段本身就有的非抗原特异性反应的缺陷，并且该单克隆抗体的特异性和敏感性高。并且，该重组抗人源TK1分子的单链抗体用于检测人血清中的TK1分子既可以克服鼠源单克隆抗体亲和力低和交叉反应导致的背景高的缺点，又可以提高小分子抗体容易进入细胞内可以提高免疫组化中检测效果。
因而，根据本发明的一个方面，本发明提供了一种单克隆抗体。根据本发明的实施例，所述单克隆抗体的轻链具有SEQ ID NO:1所示的氨基酸序列，具体地，SEQ ID NO:1所示的氨基酸序列可以是轻链可变区序列，重链具有SEQ ID NO:2所示的氨基酸序列，具体地，SEQ ID NO:2所示的氨基酸序列可以是重链可变区序列。
Figure PCTCN2019102619-appb-000001
根据本发明实施例的单克隆抗体为重组的抗TK1的IgY单克隆抗体，亲和力高，交叉反应低，有效避免了IgG的非特异性反应，并且相对于IgG，本发明实施例的单克隆抗体的相对于分子量更小，更容易进入到细胞内，可以提高免疫组化中检测效果，并且，易于通 过血管壁和实体瘤，可以有利于作用药物进行治疗。
另外，根据本发明上述实施例的单克隆抗体还可以具有如下附加的技术特征：
根据本发明的实施例，该单克隆抗体进一步包括：连接肽，所述连接肽具有SEQ ID NO:3所示的氨基酸序列。由此，连接肽连接轻链可变区的C端和重链可变区的N端，形成单克隆抗体。并且，该连接肽具有良好的柔性，不会影响重链可变区和轻链可变区的正确折叠。
根据本发明的实施例，所述单克隆抗体进一步包括下列表达元件的至少一种：信号肽，所述信号肽具有SEQ ID NO:4所示的氨基酸序列；标签，所述标签具有SEQ ID NO:5所示的氨基酸序列。其中，信号肽引导重组的单克隆抗体分泌的到细胞外，有利于于重组的单克隆抗体的纯化。根据本发明的实施例，信号肽与所述单克隆抗体的轻链可变区的N端相连。本发明实施例的信号肽为CHO表达系统抗体重组常用的鼠IL-2信号肽；而连接肽用于将标签序列连接到抗体上，通过标签序列对抗体进行分离，其中，该标签为人流感病毒血凝素9肽。该标签可以与该单克隆抗体的重链可变区的C端相连。
Figure PCTCN2019102619-appb-000002
根据本发明的实施例，所述单克隆抗体具有SEQ ID NO:6所示的氨基酸序列。
Figure PCTCN2019102619-appb-000003
根据本发明的第二方面，本发明提供了一种单链抗体。根据本发明的实施例，所述单链抗体的轻链具有SEQ ID NO:1所示的氨基酸序列，重链具有SEQ ID NO:2所示的氨基酸序列。
本文所用术语“单链抗体”是由抗体重链可变区和轻链可变区通过短肽(linker)连接而成的抗体。具体地，单链抗体没有恒定区，但本发明实施例的单链抗体和单克隆抗体的功能和免疫效果是相同和相近的。
根据本发明的实施例，该单链抗体进一步包括：连接肽，所述连接肽具有SEQ ID NO:3所示的氨基酸序列。由此，连接肽连接轻链可变区的N端和重链可变区的C端，形成单链抗体。并且，该连接肽具有良好的柔性，不会影响重链可变区和轻链可变区的正确折叠。
根据本发明的实施例，所述单链抗体进一步包括下列表达元件的至少一种：信号肽，所述信号肽具有SEQ ID NO:4所示的氨基酸序列；标签，所述标签具有SEQ ID NO:5所示的氨基酸序列。其中，信号肽引导重组的单链抗体分泌的到细胞外，有利于于重组的单链抗体的纯化。本发明实施例的信号肽为CHO表达系统抗体重组常用的鼠IL-2信号肽；而连接肽用于将标签序列连接到抗体上，通过标签序列对抗体进行分离，其中，该标签为人流 感病毒血凝素9肽。
根据本发明的第三方面，本发明提供了一种核酸。根据本发明的实施例，所述核酸编码前述的单克隆抗体或单链抗体。发明人惊奇地发现，该核酸编码的抗TK1的IgY单链抗体或者单克隆抗体，亲和力高，交叉反应低，有效避免了哺乳动物IgG的非特异性反应，并且相对于IgG，该单链抗体或者单克隆抗体的相对于分子量更小，更容易进入到细胞内，可以提高免疫组化中检测效果，并且，易于通过血管壁和实体瘤，可以有利于作用药物进行治疗。
根据本发明的实施例，所述核酸进一步包括下列表达元件的至少一种：
KOZAK序列，所述KOZAK序列具有SEQ ID NO:7所示的核苷酸序列，它可以与翻译起始因子结合而介导含有5’帽子结构的mRNA翻译起始。
Figure PCTCN2019102619-appb-000004
信号肽，所述信号肽具有SEQ ID NO:8所示的核苷酸序列，信号肽引导重组的单链抗体分泌的到细胞外。
Figure PCTCN2019102619-appb-000005
标签，所述标签具有SEQ ID NO:9所示的核苷酸序列，通过标签序列对抗体进行分离，其中，该标签为人流感病毒血凝素的序列
Figure PCTCN2019102619-appb-000006
根据本发明的实施例，所述核酸具有SEQ ID NO:10所示的核苷酸序列。
Figure PCTCN2019102619-appb-000007
其中，3‘端的AGATCT序列和5端的CCGCGG为酶切位点。
其中，需要说明的是，DNA转录成mRNA，mRNA经剪接等加工后翻译出蛋白质，所谓编码序列就是与蛋白质序列一一对应的DNA序列，且该序列中间不含其它非该蛋白质对应的序列，不考虑mRNA加工等过程中的序列变化，总之，编码序列就是与蛋白质的密码 子完全对应，换句话说，编码序列就是编码一段蛋白产物的序列。
在本发明中，该核酸还包括对SEQ ID NO：10所示的核苷酸序列进行一个或多个碱基的取代、缺失、添加修饰的核苷酸序列，是指分别或同时在所述核苷酸序列的5’端和/或3’端，和/或序列内部进行例如不超过2-60个，或者不超过2-40个，或者不超过3-30个，或者不超过4-15个，或者不超过5-10个，或者不超过6-8个的分别用逐个连续整数表示的碱基的取代、缺失、添加修饰。
在本发明中，该核酸还包括对SEQ ID NO：10所示的核苷酸序列进行如上述一个或多个碱基的取代、缺失、添加修饰的核苷酸序列具有与SEQ ID NO：10所示的核苷酸序列相同或相似的抗TK1单链抗体或者单克隆抗体功能。
根据本发明的第四方面，本发明提供了一种重组载体。根据本发明的实施例，所述重组载体包含前述的核酸。根据本发明实施例的载体导入受体细胞后，能分泌产生抗TK1单链抗体或者单克隆抗体，该单链抗体或者单克隆抗体的免疫反应性好、亲和力高，交叉反应低，有效避免了IgG的非特异性反应，并且相对于IgG，该单链抗体或者单克隆抗体的相对于分子量更小，更容易进入到细胞内，可以提高免疫组化中检测效果，并且，易于通过血管壁和实体瘤，可以有利于作用药物进行治疗。
该载体可以通过例如将上述核苷酸序列插入克隆载体或表达载体而得到，或者可以通过人工合成得到。
根据本发明的实施例，所述重组载体的载体为真核载体，例如pIRES2-EGFP载体。由此，含有哺乳动物细胞表达所需的调控原件，能在哺乳动物细胞中分泌表达抗人TK1单链抗体。
根据本发明的第五方面，本发明提供了一种重组细胞。根据本发明的实施例，该重组细胞含有前述的载体。根据本发明实施例的重组细胞能分泌产生抗TK1单链抗体或者单克隆抗体，该单链抗体或者单克隆抗体的免疫反应性好、亲和力高，交叉反应低，有效避免了IgG的非特异性反应，并且相对于IgG，该单链抗体或者单克隆抗体的相对于分子量更小，更容易进入到细胞内，可以提高免疫组化中检测效果，并且，易于通过血管壁和实体瘤，可以有利于作用药物进行治疗。
根据本发明的一些实施例，该重组细胞可以通过将前述载体转化至宿主细胞而得到。本发明实施例的真核核表达载体转染CHO细胞(中国仓鼠卵巢细胞，属于一种卵巢成纤维肿瘤细胞)16小时可以观察明显的表达(绿色荧光蛋白标记)。
根据本发明的第六方面，本发明提供了一种制备前述的单克隆抗体或前述单链抗体的方法。根据本发明的实施例，该方法包括：将前述的重组细胞在适于蛋白表达和分泌的条件下进行培养，以便获得所述单克隆抗体或单链抗体。由此，利用该方法制备的单克隆抗体或者单链抗体具有免疫反应性好、亲和力高，交叉反应低，有效避免了IgG的非特异性反应，并且相对于IgG，该单链抗体或者单克隆抗体的相对于分子量更小，更容易进入到细胞内，可以提高免疫组化中检测效果，并且，易于通过血管壁和实体瘤，可以有利于作用 药物进行治疗。
根据本发明的一些实施例，该方法还包括对该单链抗体或者单克隆抗体进行纯化处理，该纯化处理可以通过TK1-31氨基酸偶联多肽抗原的琼脂糖凝胶柱亲和层析进行。由此，该纯化处理得到的单链抗体或者单克隆抗体纯度和活性高。
根据本发明的第七方面，本发明提供了一种免疫偶联物。根据本发明的实施例，该免疫偶联物包括：前述的单克隆抗体，或者前述的单链抗体；以及选自下组的偶联部分：药物、毒素、细胞因子、放射性核素或酶。根据本发明实施例的免疫偶联物，通过偶联前述的单链抗体或者单克隆抗体，能有效提高偶联部分的药物效果，对细胞异常疾病，例如组织增生和肿瘤等的疗效更佳。
根据本发明的第八方面，本发明提供了一种检测条或检测试剂盒。根据本发明的实施例，该检测条和检测试剂盒含有前述的单克隆抗体、前述的单链抗体、前述的免疫偶联物、或它们与可检测标记物的结合物。由此，该检测条或检测试剂盒能用于检测TK1，进而判断细胞的异常增殖情况。并且该检测条或检测试剂盒的检测灵敏度高、特异性好。
根据本发明的一个优选实施例中，该可检测标记物选自：胶体金标记、荧光标记、同位素标记、酶标记，优选该酶标记为HRP酶标。
根据本发明的第八方面，本发明提供了前述的单克隆抗体、前述的单链抗体、前述的免疫偶联物和前述的检测条或检测试剂盒在检测细胞异常增殖的用途。由此，利用前述的单克隆抗体或者单链抗体、前述的免疫偶联物和前述的检测条或检测试剂盒通过检测TK1，进而判断细胞的异常增殖情况，检测灵敏度高、特异性好。
其中，细胞异常增殖的情况有多种，针对本发明实施例的抗TK1单克隆抗体或者单链抗体，该细胞异常增殖可以包括怀孕、组织增生和肿瘤，检测的灵敏度和准确率高。
本发明的附加方面和优点将在下面的描述中部分给出，部分将从下面的描述中变得明显，或通过本发明的实践了解到。
附图说明
本发明的上述和/或附加的方面和优点从结合下面附图对实施例的描述中将变得明显和容易理解，其中：
图1显示了根据本发明一个实施例的单链抗体的PCR鉴定结果示意图；
图2显示了根据本发明一个实施例的双酶切琼脂糖电泳结果示意图；
图3显示了根据本发明一个实施例的单链抗体基因真核表达载体转染CHO细胞的荧光显微观察图片示意图。
具体实施方式
下面详细描述本发明的实施例，所述实施例的示例在附图中示出，其中自始至终相同或类似的标号表示相同或类似的元件或具有相同或类似功能的元件。下面通过参考附图描述的实施例是示例性的，仅用于解释本发明，而不能理解为对本发明的限制。
下面参考具体实施例，对本发明进行说明，需要说明的是，这些实施例仅仅是说明性的，而不能理解为对本发明的限制。
下面将结合实施例对本发明的方案进行解释。本领域技术人员将会理解，下面的实施例仅用于说明本发明，而不应视为限定本发明的范围。实施例中未注明具体技术或条件的，按照本领域内的文献所描述的技术或条件(例如参考J.萨姆布鲁克等著，黄培堂等译的《分子克隆实验指南》，第三版，科学出版社)或者按照产品说明书进行。所用试剂或仪器未注明生产厂商者，均为可以通过市购获得的常规产品，例如可以采购自Sigma公司。
实施例1
本发明实施例所提供的的抗TK1单链抗体的表达方法如下：
1、哺乳动物细胞表达系统的构建：
1.1引物设计
根据真核表达需要的调控元件和具有原核活性的单链抗体基因序列，设计从单链抗体基因文库中扩增鸡IgY抗体可变区基因的上下游引物序列:
TK1SCFVHVFP
5’:GAAGATCTGCCACCATGGGCAGGATGCAACTCCTGTCTTGCATTGCACTAAGTCTTGCACTTGTCACAAACAGTGCGCTGACTCAGCCGTCCTC-3’(SEQ ID NO:11)
TK1SCFVLVRP
5’：CGGGATCCTTAAGCGTAGTCTGGGACGTCGTATGGGTAAGAGGAGACGATGACTTCGG-3’(SEQ ID NO:12)
1.2基因克隆
以噬菌体展示系统筛选出具有对人源分子TK1的C端31肽活性的单链抗体基因为模板，应用设计的一对引物，按照下列程序扩增适宜真核表达载体构建的序列。其中胸苷激酶1(TK1)分子基因全长702bp，编码234个氨基酸，C端31肽位于全长蛋白分子的第195～225aa位。
扩增体系：PCR反应体系：10*PCR buffer
Figure PCTCN2019102619-appb-000008
扩增参数：
Figure PCTCN2019102619-appb-000009
Figure PCTCN2019102619-appb-000010
扩增的序列包含构建需要的酶切位点，真核表达需要的kozak序列GCCACCATGG，动物细胞分泌表达需要的N端信号肽MGRMQLLSCIALSLALVTNS序列、连接重轻链可变区的linker序列GGGSGGGGSGGGGSGGGS、用于检测和纯化的标签序列(人流感病毒血凝素9肽，YPYDVPDYA序列)。
将PCR扩增的产物琼脂糖电泳鉴定，并回收目的片段。
1.3表达载体和目的基因的连接
将电泳纯化回收的片段，和表达载体pIRSE2-EGFP分别用BglⅡ和SacⅡ进行双酶切，酶切后电泳回收单链抗体片段和载体线性化片段，以除去切除的两端的小片段和酶蛋白分子，将两种回收的片段以等摩尔比例混合用T4连接酶连接，得到连接目的基因的表达载体。
1.3.1、BglⅡ酶切
Pires2-EGFP质粒2ug/scfv基因PCR扩增产物1ug,10*NEB Buffer 5ul，Bg1Ⅱ酶1ul灭菌去离子水至50ul，37℃酶切过夜(14h)，产物用乙醇/醋酸钠沉淀法纯化回收。
1.3.2 SacⅡ酶切
BglⅡ酶切回收产物，10*cutsmart Buffer 5ul，SacⅡ酶1ul，灭菌去离子水至50ul，37℃1h，产物电泳Qiagen胶回收试剂盒纯化回收。
1.3.3酶链接与转化
取Pires2-EGFP双酶切的产物与scAB-pMoPac PCR扩增产物的双酶切产物(载体：插入片段的摩尔比约为1:3)其中，载体约200ng，2*酶链接buffer 10ul，T4连接酶1ul，水至20ul，16℃链接过夜，产物用乙醇/醋酸钠沉淀法纯化回收(20ul)。取1ul回收产物加入40ulDH5α感受态细胞冰上静置2min，加入预冷的1mm电转杯中，1.8KV，5mm电转，立即加入1mlSOC培养基，取出200r/min，振荡培养1h，取出加到含50ug/ml kana抗性的SOB平板，37℃过夜培养。
1.4表达载体的鉴定
将连接产物直接热冲击转化或电转化DH5α感受态细胞(Solarbio,C1100)，转化后将所有转化的细菌铺到含有卡那霉素的琼脂平板上，37℃倒置培养16～20小时(h)，从平板上生长的细菌菌落中，于37℃过夜后，挑取5-10个菌落，置于5毫升(mL)含卡那霉素的LB培养基中培养16h，提取质粒。将质粒纯化后用BglⅡ和SacⅡ进行双酶切，能够切得800bp片段的克隆(如图1所示)，进行序列测定，再次进行目的基因的确定。将测定的序列用DNAMANV6进行序列分析，测定的序列与设计的优化序列完全相同。将转化子进行单链抗体基因PCR扩增阳性的转化子菌落进行扩增培养，提取质粒DNA，然后用BglⅡ和Sac Ⅱ进行双酶切鉴定，结果如图2所示，结果显示可以产生于单链抗体基因大小一致的DNA片段。将鉴定大小正确的质粒DNA送金斯瑞生物技术公司进行序列测定，测定的序列与设计的优化序列完全相同。
2、哺乳动物细胞CHO的转染
中国仓鼠卵巢细胞(Chinese Hamster Ovary，CHO)，1957年美国科罗拉多大Dr.Theodore T.Puck从一成年雌性仓鼠卵巢分离获得，为上皮贴壁型细胞，是生物工程上广泛使用的细胞系。该细胞具有不死性，可以传代百代以上。另外CHO细胞在基因工程使用中还有一个优点，该细胞属于成纤维细胞(Fibroblast)，是一种非分泌型细胞，它本身很少分泌CHO内源蛋白，因此对目标蛋白分离纯化工作十分有利。并且CHO细胞可形成有活性的二聚体，具有糖基化的功能，为表达复杂生物大分子的理想宿主，获得的抗体蛋白具有与人自然产生的蛋白完全相似的生物学特性。本实施例中，以CHO细胞作为表达载体的宿主细胞。
2.1细胞准备
选择24孔细胞培养板在每一孔中，在转染前24小时传代CHO细胞，转染日细胞达到70％～90％的丰盈度，其中，丰盈度为70％～90％时，悬浮细胞转染时应处于对数生长期。
2.2载体DNA准备
在100μL/孔无血清DMEM或其他无血清生长培养基中稀释1μg“步骤1”构建好的载体DNA后，按照每1μgDNA：2μL的转染剂TurboFect，按该比例进行混合，转染效率高。旋涡震荡充分混合均匀，添加到稀释后的载体DNA中2μL/孔。
2.3转染细胞
将混合后的载体DNA和转染剂TurboFect室温下孵育15～20分钟，取100μL转染试剂/DNA的混合液加入培养基进行孵育。孵育过程中，不要移除培养基，轻轻地摇动板，以达到复合物的均匀分布。在37℃的二氧化碳孵化器中孵育，从而得到转染细胞。
2.4表达检测
2.4.1荧光显微检测
转染后48h后，通过观察细胞荧光蛋白表达，结果如图3所示，呈现绿色荧光的细胞约占细胞总数的75％以上，因绿色荧光的选择性标志蛋白，与单链抗体基因在同一个表达调控原件调控序列内，表面各种调控原件工作正常。
2.4.2间接ELISA检测
重组IgY的单链抗体不仅含有与TK1结合的超变区，也含有高度保守的骨架区(FR)，在本实施例中还添加了人流感血凝素的HA的9肽标签。因此，在间接ELISA检测重组的单链抗体时，分别应用生物素标记的抗全长IgY二抗和辣根过氧化物酶标记的抗人流感血凝素的HA的9肽的单克隆抗体为标记抗体，检测在CHO细胞中表达的重组抗TK1单链抗体。收集转染细胞的上清，通过ELISA实验，检测重组单链抗体的表达水平，具体方法如下：
(1)将重组TK1蛋白以1x包被液稀释成0.5ug/ml浓度，每孔100μl，4℃过夜包被。
(2)洗板机400μl/孔洗涤ELISA板1次。加入封闭液200μl/孔，37℃封闭1小时。
(3)洗板机400μl/孔洗涤ELISA板1次，分别加入100μl/孔转染细胞上清、正常CHO细胞空白上清和稀释的IgY阳性对照，37℃反应1小时。
(4)洗板机400μl/孔洗涤ELISA板3次，分别加入1:20000稀释的HRP标记羊抗鼠IgG二抗和生物素标记的抗全长IgY二抗及辣根过氧化物酶标记的链霉亲和素)，100μl/孔。
(5)37℃反应1小时。洗板机400μl/孔洗涤ELISA板3次，加入单组份TMB显色液Ⅶ100μl/孔。37℃10-15分钟。
(6)加终止液50μl/孔终止反应。ELISA板放入酶标仪中，以620nm为参考波长，450nm波长测定吸光度。
据酶标仪读数判定每孔对应的转染细胞上清抗体与对照空白CHO上清及纯化IgY阳性对照的比较，包被TK1抗原与空白抗原对照比较，结果如下表所示：
Figure PCTCN2019102619-appb-000011
结果显示：用抗全长IgY生物素标记驴IgG抗体为标记抗体，转染单链抗体基因的CHO细胞上清的OD值是没有转染的CHO细胞上清的OD的6.6倍，重组TK1抗原与阴性抗原对照的比值为6.9；用抗人流感血凝素的HA的9肽的单克隆抗体为标记抗体检测的重组单链抗体的检测结果显示，转染单链抗体基因的CHO细胞上清的OD值是没有转染的CHO细胞上清的OD的2.6倍，重组TK1抗原与阴性抗原对照的比值为0.287。因此，应用两种标签检测都证明，转染单链抗体基因在CHO细胞中呈现明显的表达。
在本说明书的描述中，参考术语“一个实施例”、“一些实施例”、“示例”、“具体示例”、或“一些示例”等的描述意指结合该实施例或示例描述的具体特征、结构、材料或者特点包含于本发明的至少一个实施例或示例中。在本说明书中，对上述术语的示意性表述不一定指的是相同的实施例或示例。而且，描述的具体特征、结构、材料或者特点可以在任何的一个或多个实施例或示例中以合适的方式结合。
尽管已经示出和描述了本发明的实施例，本领域的普通技术人员可以理解：在不脱离本发明的原理和宗旨的情况下可以对这些实施例进行多种变化、修改、替换和变型，本发明的范围由权利要求及其等同物限定。

Claims (19)

  1. 一种单链抗体，其特征在于，所述单链抗体的轻链具有SEQ ID NO:1所示的氨基酸序列，重链具有SEQ ID NO:2所示的氨基酸序列。
  2. 根据权利要求1所述的单链抗体，其特征在于，所述单链抗体进一步包括：
    连接肽，所述连接肽具有SEQ ID NO:3所示的氨基酸序列。
  3. 根据权利要求1所述的单链抗体，其特征在于，所述单链抗体进一步包括下列表达元件的至少一种：
    信号肽，所述信号肽具有SEQ ID NO:4所示的氨基酸序列；
    标签，所述标签具有SEQ ID NO:5所示的氨基酸序列。
  4. 根据权利要求1所述的单链抗体，其特征在于，所述单链抗体具有SEQ ID NO:6所示的氨基酸序列。
  5. 一种单克隆抗体，其特征在于，所述单克隆抗体的轻链具有SEQ ID NO:1所示的氨基酸序列，重链具有SEQ ID NO:2所示的氨基酸序列。
  6. 根据权利要求5所述的单克隆抗体，其特征在于，所述单克隆抗体进一步包括：
    连接肽，所述连接肽具有SEQ ID NO:3所示的氨基酸序列。
  7. 根据权利要求5所述的单克隆抗体，其特征在于，所述单克隆抗体进一步包括下列表达元件的至少一种：
    信号肽，所述信号肽具有SEQ ID NO:4所示的氨基酸序列；
    标签，所述标签具有SEQ ID NO:5所示的氨基酸序列。
  8. 根据权利要求5所述的单克隆抗体，其特征在于，所述单克隆抗体具有SEQ ID NO:6所示的氨基酸序列。
  9. 一种核酸，其特征在于，所述核酸编码权利要求1～4中任一项所述的单克隆抗体或权利要求5～8中任一项所述的单链抗体。
  10. 根据权利要求9所述的核酸，其特征在于，所述核酸进一步包括下列表达元件的至少一种：
    KOZAK序列，所述KOZAK序列具有SEQ ID NO:7所示的核苷酸序列；
    信号肽，所述信号肽具有SEQ ID NO:8所示的核苷酸序列；
    标签，所述标签具有SEQ ID NO:9所示的核苷酸序列。
  11. 根据权利要求9所述的核酸，其特征在于，所述核酸具有SEQ ID NO:10所示的核苷酸序列。
  12. 一种重组载体，其特征在于，所述重组载体包含权利要求9～11中任一项所述的核酸。
  13. 根据权利要求12所述的重组载体，其特征在于，所述重组载体的载体为pIRES2-EGFP载体。
  14. 一种重组细胞，其特征在于，所述重组细胞含有权利要求12或13所述的重组载 体。
  15. 一种制备权利要求1～4中任一项所述的单链抗体或权利要求5～8中任一项所述的单克隆抗体的方法，其特征在于，包括：
    将权利要求14所述的重组细胞在适于蛋白表达和分泌的条件下进行培养，以便获得所述单链抗体或所述单克隆抗体。
  16. 一种免疫偶联物，其特征在于，包括，
    权利要求1～4中任一项所述的单链抗体，或者权利要求5～8中任一项所述的单克隆抗体；以及
    选自下组的偶联部分：药物、毒素、细胞因子、放射性核素或酶。
  17. 一种检测条或检测试剂盒，其特征在于，所述检测条和检测试剂盒含有权利要求1～4中任一项所述的单链抗体、权利要求5～8中任一项所述的单克隆抗体或权利要求16所述的免疫偶联物，
    或它们与可检测标记物的结合物。
  18. 权利要求1～4中任一项所述的单链抗体、权利要求5～8中任一项所述的单克隆抗体、权利要求16所述的免疫偶联物和/或权利要求17所述的检测条或检测试剂盒在检测细胞异常增殖的用途。
  19. 根据权利要求18所述的用途，其特征在于，所述细胞异常增殖包括怀孕、组织增生和肿瘤。
PCT/CN2019/102619 2018-09-04 2019-08-26 哺乳动物细胞重组抗人tk1的鸡源的单克隆抗体、单链抗体及其制备方法和应用 WO2020048341A1 (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US17/191,710 US20210277147A1 (en) 2018-09-04 2021-03-04 Development of recombinant chicken igy monoclonal antibody and scfv antibodies raised against human tymidine kinase 1 expressed in mammalian cells and use thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201811026810.9A CN110872354B (zh) 2018-09-04 2018-09-04 哺乳动物细胞重组抗人tk1的鸡源的单克隆抗体、单链抗体及其制备方法和应用
CN201811026810.9 2018-09-04

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US17/191,710 Continuation US20210277147A1 (en) 2018-09-04 2021-03-04 Development of recombinant chicken igy monoclonal antibody and scfv antibodies raised against human tymidine kinase 1 expressed in mammalian cells and use thereof

Publications (1)

Publication Number Publication Date
WO2020048341A1 true WO2020048341A1 (zh) 2020-03-12

Family

ID=69716963

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2019/102619 WO2020048341A1 (zh) 2018-09-04 2019-08-26 哺乳动物细胞重组抗人tk1的鸡源的单克隆抗体、单链抗体及其制备方法和应用

Country Status (3)

Country Link
US (1) US20210277147A1 (zh)
CN (1) CN110872354B (zh)
WO (1) WO2020048341A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024078017A1 (zh) * 2022-10-10 2024-04-18 华瑞同康生物技术（深圳）有限公司 鸡源抗人TK1重组IgY单链抗体和鸡源抗人TK1重组全长单克隆IgY抗体及应用

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112646039B (zh) * 2021-01-06 2022-07-22 华瑞同康生物技术（深圳）有限公司 Tk1抗体、试剂盒及其用途

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1414017A (zh) * 2002-09-13 2003-04-30 深圳市华瑞同康生物技术有限公司 抗细胞质胸苷激酶－IgY的制备及肿瘤诊断组合物
CN101027085A (zh) * 2004-05-21 2007-08-29 杨伯翰大学 抗胸苷激酶单克隆抗体的抗癌活性
CN101186922A (zh) * 2007-12-21 2008-05-28 丁克祥 一种基因免疫制备人类ⅰ型胸苷激酶单克隆抗体的新方法
CN102432683A (zh) * 2011-10-28 2012-05-02 周际 一种多表位tk1抗体的制备及其在肿瘤患者早期复发风险及预后评估中的应用
CN105980407A (zh) * 2013-12-19 2016-09-28 阿洛赛尔公司 单克隆抗tk1抗体
WO2017025944A2 (en) * 2015-08-13 2017-02-16 Brigham Young University Macrophage car (moto-car) in imunotherapy
US20190070276A1 (en) * 2015-05-20 2019-03-07 Kim Leslie O'Neill Use of Car and Bite Technology Coupled with an SCFV from an Antibody Against Human Thymidine Kinase 1 to Specifically Target Tumors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9156914B2 (en) * 2006-12-19 2015-10-13 Ablynx N.V. Amino acid sequences directed against a metalloproteinase from the ADAM family and polypeptides comprising the same for the treatment of ADAM-related diseases and disorders
JP5765814B6 (ja) * 2009-10-21 2018-06-27 国立大学法人広島大学 インテグリンα８β１特異的モノクローナル抗体
CN102504027B (zh) * 2011-10-28 2013-10-30 周际 一种多表位tk1抗体的制备及其在人群体检筛查中早期肿瘤检测和风险预警中的应用
JP5733546B2 (ja) * 2012-03-28 2015-06-10 国立大学法人広島大学 インテグリンα８β１の機能を阻害する事による線維化の抑制
CN102746397A (zh) * 2012-07-03 2012-10-24 上海交通大学 一种鸡源性抗鸡新城疫病毒p蛋白的单链抗体zl2、其制备方法及其用途
JP6525214B2 (ja) * 2014-06-03 2019-06-05 国立研究開発法人農業・食品産業技術総合研究機構 抗体またはその可変領域を含む抗体断片、抗原ポリペプチド、およびその利用
CN105821010B (zh) * 2016-05-11 2019-12-24 江苏康缘瑞翱生物医药科技有限公司 一种表达鸡ibdv抗体的重组ndv及其在制备双价疫苗中的应用
EP3645039A4 (en) * 2017-06-27 2021-05-05 Neuracle Science Co., Ltd USE OF ANTI-FAM19A5 ANTIBODIES TO TREAT FIBROSIS

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1414017A (zh) * 2002-09-13 2003-04-30 深圳市华瑞同康生物技术有限公司 抗细胞质胸苷激酶－IgY的制备及肿瘤诊断组合物
CN101027085A (zh) * 2004-05-21 2007-08-29 杨伯翰大学 抗胸苷激酶单克隆抗体的抗癌活性
CN101186922A (zh) * 2007-12-21 2008-05-28 丁克祥 一种基因免疫制备人类ⅰ型胸苷激酶单克隆抗体的新方法
CN102432683A (zh) * 2011-10-28 2012-05-02 周际 一种多表位tk1抗体的制备及其在肿瘤患者早期复发风险及预后评估中的应用
CN105980407A (zh) * 2013-12-19 2016-09-28 阿洛赛尔公司 单克隆抗tk1抗体
US20190070276A1 (en) * 2015-05-20 2019-03-07 Kim Leslie O'Neill Use of Car and Bite Technology Coupled with an SCFV from an Antibody Against Human Thymidine Kinase 1 to Specifically Target Tumors
WO2017025944A2 (en) * 2015-08-13 2017-02-16 Brigham Young University Macrophage car (moto-car) in imunotherapy

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHEN HONGXIU ET AL.: "Progress on chicken monoclonal antibody technology", PROGRESS IN BIOCHEMISTRY AND BIOPHYSICS, vol. 37, no. 4, 15 April 2010 (2010-04-15), pages 358 - 363, ISSN: 1000-3282 *
SPILLNER, E: "Avian IgY antibodies and their recombinant equivalents in research, diagnostics", BIOLOGICALS, 28 June 2012 (2012-06-28), XP055689931, ISSN: 1045-1056 *
WU, C.: "Production and characterisation of a novel chicken IgY antibody raised against C-terminal peptide from human thymidine kinase 1", JOURNAL OF IMMUNOLOGICAL METHODS, 1 June 2003 (2003-06-01), XP004430555, ISSN: 0022-1759, DOI: 10.1016/S0022-1759(03)00062-0 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024078017A1 (zh) * 2022-10-10 2024-04-18 华瑞同康生物技术（深圳）有限公司 鸡源抗人TK1重组IgY单链抗体和鸡源抗人TK1重组全长单克隆IgY抗体及应用

Also Published As

Publication number Publication date
US20210277147A1 (en) 2021-09-09
CN110872354A (zh) 2020-03-10
CN110872354B (zh) 2022-11-01

Similar Documents

Publication Publication Date Title
JP2022191318A (ja) 抗ｇｐｃ３抗体
CN109796531B (zh) 猪Delta冠状病毒N蛋白单克隆抗体及其抗原表位和应用
CN110857322A (zh) 抗人claudin 18.2单克隆抗体及其应用
WO2020125120A1 (zh) 一种抗体文库的构建方法及其应用
WO2016039321A1 (ja) がん細胞特異的な抗体、抗がん剤、及びがんの検査方法
US10882900B2 (en) Monoclonal antibody of human-derived procalcitonin, and preparation method and application thereof
US20210277147A1 (en) Development of recombinant chicken igy monoclonal antibody and scfv antibodies raised against human tymidine kinase 1 expressed in mammalian cells and use thereof
CN111825767B (zh) 一种人表皮生长因子受体2的单域抗体、检测试剂盒及其应用
CN114450292A (zh) 断裂型内含肽、使用其的重组多肽的制备方法
KR20120118918A (ko) 인간화 항-ｅｍａｐｉｉ 항체 및 이의 용도
US20210189010A1 (en) Development of recombinant chicken igy scfv antibody raised against human tymidine kinase 1 expressed in prokaryotic cells and use thereof
CN111647081B (zh) 一种重组小鼠抗人白介素19单克隆抗体、制备方法和应用
CN117362431B (zh) 抗小鼠白细胞介素10的兔单克隆抗体及其应用
CN109734804B (zh) 针对H3K64Ac/H3K64片段的纳米抗体及其应用
CN116535510A (zh) 一种抗人pla2r的抗体、试剂盒及其应用
CN107686519B (zh) 抗小鼠mxra7单克隆抗体的制备方法及其应用
CN111647086B (zh) 一种重组小鼠抗人肌酸激酶单克隆抗体、制备方法和应用
JPWO2015186721A1 (ja) 抗体またはその可変領域を含む抗体断片、抗原ポリペプチド、およびその利用
CN110894235B (zh) 一种抗隐球菌夹膜多糖的兔源单克隆抗体及其应用
JP6574033B2 (ja) Ｗｎｔ蛋白質の製造方法および保存方法
WO2018225781A1 (ja) ヒストンｈ３トリメチル化リシン特異的モノクローナル抗体又はその抗原結合性断片
CN111763255A (zh) 一种经基因修饰的vegfa蛋白及其单克隆抗体与应用
CN111647083B (zh) 一种重组小鼠抗人血幼素单克隆抗体、制备方法和应用
CN117487018B (zh) 抗人附睾分泌蛋白4的兔单克隆抗体及其应用
JP7181523B2 (ja) 糖鎖をエピトープとして特異的に認識する新規抗体及びその用途

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19857342

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 08/07/2021)

122 Ep: pct application non-entry in european phase

Ref document number: 19857342

Country of ref document: EP

Kind code of ref document: A1